Equites Radar

CLOV · Clover Health Investments, Corp

Healthcare PlansUnited StatesAnalyst view: Buy

$4.32

+1.52% last session

End-of-day data · updated 2026-07-28

Neutral2 bullish · 2 bearish technical signals
Consensus: Buy (2.33 from 3 analysts)
To mean target: +6.0%

Market cap

$2B

Enterprise value

$2B

Trailing P/E

Forward P/E

42.7

Dividend yield

Beta

2.42

Avg volume

8M

Employees

1K

2D change

5D change

-6.15%

10D change

-7.58%

30D change

-21.07%

60D change

7.29%

MTD change

-20.78%

YTD change

81.70%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.33
Covering analysts3
Mean price target$4.58
Low price target$3.50
Upside to mean target+6.0%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)43.9
50-day MA$4.47
200-day MA$2.95
Price vs 50-day MA-3.0%
Price vs 200-day MA+47.0%
MACD histogram-0.08
Volume vs 3-month avg0.5×
52w low $1.7052w high $5.41

Analyst sentiment over time — CLOV

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-21

Latest call per bank · past 12 months

UBS

Neutral

$4.75

+10.0% vs price
▲ raised from $2.75Maintains · 2026-06-11

Recent rating actions

DateFirmActionRatingPrice target
2026-07-21Canaccord GenuityMaintainsBuy$4.20 $5.50
2026-06-11UBSMaintainsNeutral$2.75 $4.75
2026-06-04Canaccord GenuityMaintainsBuy$3.20 $4.20
2026-03-20Canaccord GenuityMaintainsBuy$3.70 $3.20
2026-03-05Leerink PartnersMaintainsMarket Perform$3.00 $2.50
2026-01-20Canaccord GenuityMaintainsBuy$3.70
2025-11-06Canaccord GenuityMaintainsBuy$4.10 $3.70
2025-08-07Canaccord GenuityMaintainsBuy$4.50 $4.10

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 44 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 3.0% below the 50-day MA ($4.47).
  • Price vs 200-day MA: Trading 47.0% above the 200-day MA ($2.95).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is negative (-0.08) — short-term momentum is fading.
  • 52-week range: Price sits between the 52-week low ($1.70) and high ($5.41).

CLOV Price Chart

Loading chart for CLOV

Fundamentals

Revenue (TTM)$2.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$0.65
Net debt / EBITDA3.6
WACC20.0%
Revenue growth62.00%
Earnings growth

About Clover Health Investments, Corp

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.

More in Healthcare Plans

Screen CLOV against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.